Judge Mostly Sets Aside Jury Ruling on Amgen-Sanofi/Regeneron Repatha Patent Case

A U.S. jury decision that said Amgen Repatha patents were valid has been mostly set aside by a judge, Reuters reported Wednesday.

–In February, a Delaware jury verdict upheld two Amgen patents related to PCSK9 antibodies.

—Regeneron Pharmaceuticals and Sanofi contended Amgen’s patent claims to the antibodies were overly broad.

–In February, the two companies said they planned to file post-trial motions in an effort to overturn the verdict and request a new trial, and would, if necessary, file an appeal with the U.S. Court of Appeals for the Federal Circuit.

https://www.marketscreener.com/AMGEN-4847/news/US-Judge-Mostly-Sets-Aside-Jury-Ruling-on-Repatha-Patents-Reuters-29126062/